Addiction News

Today’s cannabis comes at a much higher potency level than that grown just 10 or 20 years ago, and with increased potency comes higher risk, according to a speaker at the Osteopathic Medical Education Conference.

Ozempic and similar drugs for diabetes and weight-related conditions were associated with a 40% lower rate of opioid overdose and 50% lower rate of alcohol intoxication in people with opioid and alcohol use disorders, a new study showed.

Nearly 5% of older adults initiate benzodiazepine after discharge for acute ischemic stroke, half of which receive up to a 30-day supply, despite known risks for cognitive decline, researchers reported in Stroke.

On Feb. 16, HHS, through its Office for Civil Rights and Substance Abuse and Mental Health Services Administration, published its final rule amending federal regulations protecting confidentiality of substance use disorder treatment records.

Teens and young adults who used cannabis had lower grades and school attendance and were less likely to complete high school or college compared with their peers who did not use cannabis, according to recent findings.

In this episode, host Hansa Bhargava, MD, discusses opioid awareness, the stigma surrounding the opioid crisis and the resources for intervention with David A. Fiellin, MD.

Higher doses of buprenorphine were associated with significantly lower rates of acute care utilization among adults with opioid use disorder compared with the FDA’s recommended dose, according to a study published in JAMA Network Open.

ORLANDO — The AAP on Monday released its first clinical guidance for prescribing opioids to children, which supports prescribing opioids when necessary and safe — although not as monotherapy and not without also providing naloxone.

The impact vaping has on DNA is just as dangerous as smoking, with both users presenting with DNA changes associated with cancer development, according to a Keck School of Medicine of University of Southern California press release.

Among young adults aged 19 to 30 years and early midlife adults aged 35 to 50 years, past-year use of cannabis and hallucinogens remained at “historically high” levels in 2023, according to the Monitoring the Future Panel Study Annual Report.